Overview:Zoticon has invested over $100 million to date in promising phase III therapeutics including two oncology products and a cardiovascular combination product. Our investors represent solid financial institutions who share our passion and commitment in bringing new drugs to patients. Zoticon creates a new company for each in-licensed late stage asset, assuring that every drug that is licensed by us receives focused developmental effort. We have the necessary qualities for a successful partnering: creativity, commitment, flexibility, experience and above all, integrity. We are supported by a strong technological, business and financial infrastructure. Our team prides itself on honesty and integrity. Our motives are not based solely on maximizing profits, and we are enthusiastic about bringing new therapies to patients. The Zoticon team is composed of seasoned entrepreneurs and investment bankers that can move quickly and decisively throughout the transaction. While a smooth transaction is clearly important, our operational teams in our portfolio companies are equally imbued with the Zoticon “Vital Spirit”. Zoticon portfolio companies are able to complete trials faster and more efficiently because that is their sole focus.